Agendia Presents Data Supporting MammaPrint’s Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference

HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands - Agendia, a world leader in molecular cancer diagnostics, today
announced that leading researchers from Agendia and the Netherlands Cancer
Institute will present data from multiple studies at the 2009 St.Gallen
Breast Cancer Conference. The St. Gallen Breast Cancer Conference, one of the
premiere conferences in breast cancer research worldwide, takes place March
11th-14th, 2009 in St.Gallen, Switzerland.

The study results further underpin the predictive and
prognostic power of Agendia’s breast cancer recurrence test, MammaPrint(R)
and will be discussed at the following poster sessions:

Thursday, 12 March 2009

Poster 0063

Comparison of MammaPrint and TargetPrint Results with Clinical
Parameters in German Patients (PATH) with Early Stage Breast Cancer

G. Kunz, T. Dimpfl, C. Jakisch, R. Buttner, F. A. de Snoo, O.
Krijgsman, E. van Lienen, A. Glas, and R. Bender.

Thursday, 12 March 2009

Poster 0071

The 70 Gene-MammaPrint Profile Allows to Identify a Subgroup
of Good-Prognostic Patients with Primary Breast Cancer and 4-9 Positive Lymph
Nodes

M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I.
Eekhout, M. Knauer, and LJ van ‘t Veer.

Thursday, 12 March 2009

Poster 0072

The 70-gene MammaPrint Prognosis Signature for Optimal Risk
Stratification in Endocrine Responsive Breast Cancer

M Knauer, EJT Rutgers, S Mook, F Cardoso, MJ van de Vijver, G
Viale, AM Glas, M. Saghatchian, M Kok, JM Bueno-de-Mesquita, SC Linn and LJ
van ‘t Veer.

Thursday, 12 March 2009

Poster 0073

The 70-gene MammaPrint Signature Is Predictive for
Chemotherapy Benefit in Early Breast Cancer

M Knauer, ME Sraver, EJT Rutgers, RA Bender, F Cardoso, S
Mook, MJ van de Vijver, M. Saghatchian, RHT Koornstra, JM Bueno-de-Mesquita,
S Rodenhuis, SC Linn and LJ van ‘t Veer.

Thursday, 12 March 2009

Poster 0074

Early Prognosis Prediction: MammaPrint on Core-needle biopsies

F. de Snoo, A. Glas, A. Floore, J. Mayordomo, A. Modollel, C.
Rolfo, LJ van ‘t Veer, E. Rutgers, S. Rodenhuis, and R. Bender.

Thursday, 12 March 2009

Poster 0075

Use of the Genomic Test MammaPrint in Daily Clinical Practice
to Assist in Risk Stratification of Young Breast Cancer Patients

G. Kunz, A. Glas and F. de Snoo, I. Simon.

About MammaPrint(R)

MammaPrint is the first ‘in vitro diagnostic multivariate
index assay’ (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA).
FDA clearance requires clinical and analytical validation and reporting
systems to ensure patient safety issues are addressed. Highly accurate,
MammaPrint identifies patients with early metastasis-those patients who are
likely to develop metastases within five years following surgery. Several
authoritative studies have shown that chemotherapy particularly reduces early
metastasis risk. In planning treatment, the MammaPrint test result provides a
doctor with a clear rationale to assess the benefit of chemotherapy in
addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia’s
CLIA-accredited service laboratory. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous FDA
clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized treatments
within reach of patients. Building on a cutting edge genomics platform for
tumor gene expression profiling, the company’s tests aim to help physicians
more accurately tailor cancer treatments. The company markets four products,
with several new genomic tests under development. In addition, Agendia
collaborates with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia was awarded the 2008
North American Oncology Clinical Diagnostics Healthcare Innovation Award by
Frost & Sullivan. Agendia is based in Huntington Beach, California, and in
Amsterdam, The Netherlands.

Source: Agendia B.V.

Media Contacts: Hans Herklots, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at agendia.com. Valerie Delva, Ricochet Public Relations, +1-212-679-3300 x131 Office, +1-917-975-3191 Mobile, vdelva at ricochetpr.com